Brought to you by 
Cougar Biotechnology reverse merges to become public
04 May 2006
Executive Summary
Cancer drug company Cougar Biotechnology completed a reverse merger with public acquisition shell SRKP 4. SRKP 4 (nonoperating and not listed at the time of the transaction) will be dissolved and Cougar is awaiting listing information and a trading symbol to become public.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Reverse Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cougar Biotechnology reverse merges to become public
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice